The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index; 59 of the 246 sources its claims cite were checked for support.
Abstract
Autism spectrum disorder (ASD) is a group of complex neurodevelopmental conditions with a heterogeneous and multifactorial etiology that is not yet fully understood. Among the various factors that may contribute to ASD development, alterations in the gut microbiota have been increasingly recognized. Microorganisms in the gastrointestinal tract play a crucial role in the gut–brain axis (GBA), affecting nervous system development and behavior. Dysbiosis, or an imbalance in the microbiota, has been linked to both behavioral and gastrointestinal (GI) symptoms in individuals with ASD. The microbiota interacts with the central nervous system through mechanisms such as the production of short-chain fatty acids (SCFAs), the regulation of neurotransmitters, and immune system modulation. Alterations in its composition, including reduced diversity or an overabundance of specific bacterial taxa, have been associated with the severity of ASD symptoms. Dietary modifications, such as gluten-free or antioxidant-rich diets, have shown potential for improving gut health and alleviating behavioral symptoms. Probiotics, with their anti-inflammatory properties, may support neural health and reduce neuroinflammation. Fecal microbiota transplantation (FMT) is being considered, particularly for individuals with persistent GI symptoms. It has shown promising outcomes in enhancing microbial diversity and mitigating GI and behavioral symptoms. However, its limitations should be considered, as discussed in this narrative review. Further research is essential to better understand the long-term effects and safety of these therapies. Emphasizing the importance of patient stratification and phenotype characterization is crucial for developing personalized treatment strategies that account for individual microbiota profiles, genetic predispositions, and coexisting conditions. This approach could lead to more effective interventions for individuals with ASD. Recent findings suggest that gut microbiota may play a key role in innovative therapeutic approaches to ASD management.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes evidence that gut microbiota dysbiosis and gut–brain axis dysfunction contribute to gastrointestinal and behavioral symptoms in autism spectrum disorder (ASD). It concludes that dietary interventions, probiotics, and fecal microbiota transplantation (FMT) show preliminary benefits but require personalized approaches and more rigorous long-term safety and efficacy data.
Key findings
- ASD affects around 1% of the global population and is diagnosed about four times more frequently in males than females; one-third of individuals with ASD have co-occurring intellectual disabilities, and 74% experience at least one co-occurring condition. GI conditions occur up to four times more frequently in children with ASD than in neurotypical peers, with prevalence rates ranging from 9% to 91%.
- ASD-associated dysbiosis includes a reduced Bacteroidetes/Firmicutes ratio, increased Lactobacillus species, and slight elevation in Desulfovibrio, which correlates with autism symptom severity; autistic children also show lower overall short-chain fatty acid levels, with a pronounced reduction in butyrate.
- In a study of 40 children with ASD aged 2–5 years, a whey-based supplement fortified with Bifidobacterium spp. and Lactobacillus spp. given daily for three months significantly increased stool colony counts of Bifidobacterium spp. (p = 0.000) and Lactobacillus spp. (p = 0.015); 80% of children had reduced anxiety and improved sleep, alongside better CARS and Pediatric Gastrointestinal Symptoms Questionnaire scores.
- A small open-label trial of microbiota transfer therapy in 18 children with ASD reported approximately 80% improvement in GI symptoms, sustained eight weeks after treatment; a two-year follow-up found most GI improvements maintained, continued positive behavioral progress, and increased bacterial diversity with higher Bifidobacteria and Prevotella.
Methods
- Narrative review; literature was selected through searches in PubMed and Google Scholar, including original research articles and systematic reviews based on recency and significance to the topic.
- Articles cited in tables included both original studies and review articles, with research conducted on both humans and animals.
- No formal systematic review, meta-analysis, or quantitative synthesis is described.
Limitations
- Stated: FMT limitations include lack of large-scale randomized controlled trials, uncertain long-term implications, variable individual responses due to microbiota/genetics/environment, and safety concerns such as infection risks and unintended microbiota changes.
- Stated: evidence for probiotics remains preliminary; further research is needed to identify effective strains, optimal dosages, and long-term safety profiles, and larger well-controlled trials and personalized probiotic treatments are required.
- Evident: as a narrative review, the selection criteria were based on recency and significance without a systematic protocol; the paper itself notes that diversity and heterogeneity of existing clinical studies challenge a robust evidence base, and microbiota findings for several taxa are conflicting.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
35 Valid · 2 Not valid · 118 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“A higher autism polygenic score (PGS) is linked to a lower likelihood of co-occurring developmental disabilities.”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 1. Introduction
What the sources say
- Disputedcites [9] Chawner S.J.R.A. Doherty J.L. Anney R.J.L. Antshel K.M. Bearden C.E. Bernier R. Chung W.K. Clements C.C. Curran S.R. Cuturilo G. A Genetics-First Approach to Dissecting the Heterogeneity of Autism: Phenotypic Comparison of Autism Risk Copy Number Variants Am. J. Psychiatry 2021 178 77 86 10.1176/appi.ajp.2020.20010015 33384013 PMC8022239 sourceExperimental — accuracy not yet measured
Our copy contains no polygenic-score analysis at all: the Discussion explicitly states that future work must investigate genetic factors 'including additional rare variants and polygenic risk, which we were not able to analyse in this study' (Discussion). All reported results concern CNV groups (16p11.2 del/dup, 22q11.2 del/dup) versus heterogeneous autism on ADI-R severity, domain/subdomain scores and FSIQ/VIQ/PIQ (Results, Aim 1 and Aim 2), and searches for 'polygenic score', 'PGS', 'polygenic risk' and 'developmental disability' returned only these passages plus references. The paper therefore contradicts rather than supports the attribution of an autism-PGS-to-developmental-disability association to it. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
- Supportedcites [10] Warrier V. Zhang X. Reed P. Havdahl A. Moore T.M. Cliquet F. Leblond C.S. Rolland T. Rosengren A. Rowitch D.H. Genetic Correlates of Phenotypic Heterogeneity in Autism Nat. Genet. 2022 54 1293 1304 10.1038/s41588-022-01072-5 35654973 PMC9470531 source
The Abstract states directly that 'higher autism polygenic scores (PGS) were associated with lower likelihood of co-occurring developmental disabilities in autistic individuals,' and the Results section 'Autism PGS and co-occurring developmental disabilities' (SPARK cohort, n = 13,435, quasi-Poisson regression) reports βPGS = −0.037, s.e. = 0.009, P = 3.91 × 10−5 for a reduced count of co-occurring developmental disabilities, holding after accounting for three other PGS. The source frames this as an association (with a possible contribution from the negative correlation with high-impact de novo variants), consistent with the citing sentence's hedged 'is linked to'. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Additionally, studies suggest a potential increase in the prevalence of Lactobacillus in the fecal samples of patients diagnosed with ASD [8,18,50,96,97,98,102,103,106,109,110,111].”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 3. The Association Between Gut Microbiota and the Development and Progression of Autism Spectrum Disorders (ASD) > 3.2. A Comparative Analysis of the Gut Microbiota in Patiens Diagnosed withASD and a Healthy Population
What the sources say
- Supportedcites [8] Fattorusso A. Di Genova L. Dell’Isola G.B. Mencaroni E. Esposito S. Autism Spectrum Disorders and the Gut Microbiota Nutrients 2019 11 521 10.3390/nu11030521 30823414 PMC6471505 source
Section 3, “Dysbiosis in Autism Spectrum Disorder” (page not provided), discusses fecal microbiome findings and reports Lactobacillus as more abundant in children with ASD than in healthy children. The finding also applies to sibling controls, but the claim’s cautious wording does not imply that the increase is unique to ASD. (LLM, conf=0.91)
- Supportedcites [18] Strati F. Cavalieri D. Albanese D. De Felice C. Donati C. Hayek J. Jousson O. Leoncini S. Renzi D. Calabrò A. New Evidences on the Altered Gut Microbiota in Autism Spectrum Disorders Microbiome 2017 5 24 10.1186/s40168-017-0242-1 28222761 PMC5320696 source
The Results section reports significantly greater relative abundance of Lactobacillus in autistic subjects than in neurotypical controls. The Methods section states that the study analyzed stool samples from enrolled subjects, supporting the claim’s reference to fecal samples. (LLM, conf=0.93)
- Disputedcites [50] De Angelis M. Piccolo M. Vannini L. Siragusa S. De Giacomo A. Serrazzanetti D.I. Cristofori F. Guerzoni M.E. Gobbetti M. Francavilla R. Fecal Microbiota and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified PLoS ONE 2013 8 e76993 10.1371/journal.pone.0076993 24130822 PMC3793965 sourceExperimental — accuracy not yet measured
The Results (Enumeration of cultivable bacteria, Table 3; page not provided) report lower counts of presumptive Enterococcus and Lactobacillus in autistic children than in healthy children, not an increase. The Introduction and Discussion describe differences in Lactobacillus composition but do not say it increased. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Dysbiosis can compromise this barrier, leading to increased intestinal permeability, commonly referred to as “leaky gut” syndrome (LGS).”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 2. Gut Microbiota and Gut–Brain Axis > 2.1. Gut–Brain Axis and Bacterial Metabolites
What the sources say
- Partly supportedcites [44] Odenwald M.A. Turner J.R. Intestinal Permeability Defects: Is It Time to Treat? Clin. Gastroenterol. Hepatol. 2013 11 1075 1083 10.1016/j.cgh.2013.07.001 23851019 PMC3758766 sourceExperimental — accuracy not yet measured
The Abstract describes barrier defects as increased intestinal permeability and discusses the term “leaky gut syndrome,” supporting those parts of the sentence. It does not say that dysbiosis compromises the barrier; its mention of microbiota describes them as luminal contents the barrier keeps from entering the body, not as a cause of barrier loss. (LLM, conf=0.84)
- Not checked yetcites [45] Wasiak J. Gawlik-Kotelnicka O. Intestinal Permeability and Its Significance in Psychiatric Disorders—A Narrative Review and Future Perspectives Behav. Brain Res. 2023 448 114459 10.1016/j.bbr.2023.114459 37121278 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Dysbiosis, characterized by alterations in the gut microbiota composition, has been implicated in the gastrointestinal and neuropsychiatric symptoms of ASD, potentially through mechanisms involving immune dysregulation, increased intestinal permeability, and disrupted gut–brain communication [8].”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 1. Introduction
What the sources say
- Supportedcites [8] Fattorusso A. Di Genova L. Dell’Isola G.B. Mencaroni E. Esposito S. Autism Spectrum Disorders and the Gut Microbiota Nutrients 2019 11 521 10.3390/nu11030521 30823414 PMC6471505 source
The Introduction (p. 1, §1) states that dysbiosis in children with ASD 'may contribute to both gastrointestinal and CNS symptoms' and links it to mucosal-barrier disruption with increased intestinal permeability, inflammatory cytokine production and disruption of gut-CNS signalling in the gut-brain axis. Section 4 (§4, 'Inflammation Hypothesis' and the following pages) elaborates the three mechanisms the claim names: dysbiosis altering gut permeability ('leaky gut') allowing LPS/toxin translocation, immune activation with raised proinflammatory cytokines modulating the CNS, and bidirectional neuroendocrine/neuroimmune-vagal gut-brain signalling affecting behaviour. The claim's hedge ('potentially') matches the review's own cautious wording, so the paraphrase is faithful. (LLM, conf=0.91)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, in the context of ASD, research findings are inconsistent [68,69].”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 2. Gut Microbiota and Gut–Brain Axis > 2.1. Gut–Brain Axis and Bacterial Metabolites
What the sources say
- Not checked yetcites [68] Açıkel S.B. Kara A. Bağcı Z. Can Ü. Serum Trimethylamine N-Oxide and Lipopolysaccharide Binding Protein Levels among Children Diagnosed with Autism Spectrum Disorder Int. J. Dev. Neurosci. 2023 83 571 577 10.1002/jdn.10287 37525434 source
- Partly supportedcites [69] Quan L. Yi J. Zhao Y. Zhang F. Shi X.-T. Feng Z. Miller H.L. Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated with Autism Spectrum Disorders Neurotoxicology 2020 76 93 98 10.1016/j.neuro.2019.10.012 31704102 PMC7385710 sourceExperimental — accuracy not yet measured
The Results report higher plasma TMAO in children with ASD than in typically developing children, providing one finding relevant to the cited comparison. But the Introduction calls this the first study to directly examine TMAO and ASD, and the Discussion does not identify conflicting TMAO findings. This source alone therefore does not establish that findings on TMAO in ASD are inconsistent. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
70 more claims · 25 with their cited sources checked
Create a free account to see all 162 claims and to verify the 187 references still open.
- Probably not a substantial claim. 29
- It may state two separate claims as one. 72
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In addition to motor symptoms, children with ASD frequently experience comorbid sleep disturbances [27,28], feeding and eating disorders (FEEDs) [29,30], and gastrointestinal symptoms such as constipation [31].”
From The Prevalence and Clinical Significance of Toe Walking in Autism Spectrum Disorder: A Cross-Sectional Study in an Italian Pediatric Sample (2025) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 1. Introduction
“The gut microbiota composition in children with autism is characterized by a reduced Bacteroidetes/Firmicutes ratio, an increased abundance of Lactobacillus species, and a slight elevation in Desulfovibrio, which correlates with the severity of autism symptoms [17].”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 1. Introduction
“Alterations in the gut microbiota of individuals with ASD, including imbalances in the abundance of Gram-negative bacteria involved in sulfur metabolism, such as an increased presence of Bilophila and a decreased abundance of Desulfovibrio, may affect the availability of sulfur metabolites and disrupt the biochemical homeostasis of the body [17,18].”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 3. The Association Between Gut Microbiota and the Development and Progression of Autism Spectrum Disorders (ASD) > 3.2. A Comparative Analysis of the Gut Microbiota in Patiens Diagnosed withASD and a Healthy Population
“Ristori et al. revealed that individuals diagnosed with ASD exhibited a reduced population of bacteria from the Ruminococcus genus; however, numerous studies have demonstrated that the population of these bacteria could be augmented [101,107,109,110].”
§ The Gut–Brain–Microbiota Connection and Its Role in Autism Spectrum Disorders > 3. The Association Between Gut Microbiota and the Development and Progression of Autism Spectrum Disorders (ASD) > 3.2. A Comparative Analysis of the Gut Microbiota in Patiens Diagnosed withASD and a Healthy Population
“Furthermore, the research conducted by Coretti et al. and Ristori et al. suggests that, in patients diagnosed with ASD, there is not only an increase in the overall prevalence of Ruminococcus bacteria but also a potential elevation in the abundance of R. torques species [101,107].”
Citations
Cites
Linking long-term dietary patterns with gut microbial enterotypes
Wu, G. D., Chen, J., Hoffmann, C., Bittinger, K., Chen, Y.-Y., Keilbaugh, S. A., Bewtra, M., Knights, D., Walters, W. A., Knight, R., et al. (2011) · Science · doi:10.1126/science.1208344 · Cited by 6,513 · cited 1×
“…the predominance of specific bacterial species, leading to two primary enterotypes: one dominated by Bacteroides , prevalent in industrialized regions with low-fiber, high-fat diets, and another dominated by Prevotella , more common in regions with high-fiber, minimally processed diets [28,29].”
Turnbaugh, P. J., Ley, R. E., Hamady, M., Fraser-Liggett, C. M., Knight, R., & Gordon, J. I. (2007) · Nature · doi:10.1038/nature06244 · Cited by 6,091 · cited 1×
“The collective genetic material of these microbes is 100 times greater than the human genome, and their combined mass is estimated at 1 to 3 kg [23,24].”
Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · cited 1×
“Butyrate plays a crucial role in regulating anti-inflammatory responses by controlling the expression of forkhead box protein P3 (Foxp3), essential for suppressing excessive inflammation [57].”
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 1×
“The collective genetic material of these microbes is 100 times greater than the human genome, and their combined mass is estimated at 1 to 3 kg [23,24].”
Global prevalence of autism: A systematic review update
Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M. S., Saxena, S., Yusuf, A., Shih, A., & Elsabbagh, M. (2022) · Autism Research · doi:10.1002/aur.2696 · Cited by 3,117 · cited 1×
“The observed increase in prevalence may reflect heightened societal awareness, improved case identification, and evolving diagnostic criteria [4].”
Lai, M.-C., Lombardo, M. V., & Baron-Cohen, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61539-1 · Cited by 2,371
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk
Zhu, W., Gregory, J. C., Org, E., Buffa, J. A., Gupta, N., Wang, Z., Li, L., Fu, X., Wu, Y., Mehrabian, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.011 · Cited by 1,968
You are what you eat: Diet, health and the gut microbiota
Zmora, N., Suez, J., & Elinav, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0061-2 · Cited by 1,792
The enteric nervous system and neurogastroenterology
Furness, J. B. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.32 · Cited by 1,619 · cited 2×
“The autonomic nervous system and ENS regulate gut secretion, motility, and immune responses, all of which influence microbiota composition [42].”
An insight into gut microbiota and its functionalities
Adak, A., & Khan, M. R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2943-4 · Cited by 1,485 · cited 1×
“Structurally, it maintains the integrity of the intestinal epithelium and supports cell regeneration [16].”
Cited by
Translocation of bacteria from the gut to the brain in mice
Thapa, M., Kumari, A. R., Chin, C., Choby, J. E., Akbari, E., Bogati, B., Jin, F., Furr, E., Chopyk, D. M., Koduri, N., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003652 · Cited by 39
Kadiyska, T., Vassilev, D. I., Tourtourikov, I., Ciurinskiene, S., Madzharova, D., Savcheva, M., Stoynev, N., Mileva-Popova, R., Tafradjiiska-Hadjiolova, R. K., & Mitev, V. (2025) · Nutrients · doi:10.3390/nu17111775 · Cited by 25
“Microbial metabolites—short-chain fatty acids (SCFAs; acetate, propionate, butyrate), aromatic compounds, free amino acids, and neurotransmitters such as γ -aminobutyric acid (GABA)—are key signaling molecules [6,13].”
Akhtar, A., & Rahaman, S. B. (2025) · Brain Sciences · doi:10.3390/brainsci15080853 · Cited by 27
“Furthermore, dietary imbalance can also destroy the flora of the gut, and even useful bacteria may lose their abundance [80].”
Galvis, C. A. N., Trejos-Gallego, D. M., Correa-Salazar, C., Triviño-Valencia, J., Buitrago, M. V., Ruiz-Pulecio, A. F., Méndez-Ramírez, L. F., Zabaleta, J., Meñaca-Puentes, M. A., Villa, C. A. R., et al. (2025) · Nutrients · doi:10.3390/nu17162664 · Cited by 18
“Multi-strain combinations are recommended by recent meta-analyses as they provide complementary metabolic and immune functions, enhancing overall therapeutic impact [8,27–29].”
Aliuş, C., Breazu, A., Panţu, C., Toader, C., Șerban, M., Covache-Busuioc, R.-A., Munteanu, O., & Dumitru, A. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210959 · Cited by 12
Sun, W., Ma, L., Feng, X., Fan, Y., Cai, Y., & Li, X. (2025) · Psychology Health & Medicine · doi:10.1080/13548506.2025.2565181 · Cited by 11
Gut microbiota: origin or panacea for all ills? Gut microbiota and systemic diseases
Colica, C., Vecchio, I., Aiello, E., Abenavoli, L., Scarlata, G. G. M., & Aiello, V. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108299 · Cited by 9
Costanza, C., Gallai, B., Sorrentino, M., Gnazzo, M., Pisanò, G., Parisi, L., Germanò, E., Maltese, A., Esposito, M., Roccella, M., et al. (2025) · Medicina · doi:10.3390/medicina61081346 · Cited by 8
“In addition to motor symptoms, children with ASD frequently experience comorbid sleep disturbances [27,28], feeding and eating disorders (FEEDs) [29,30], and gastrointestinal symptoms such as constipation [31].”
Gut Microbiota and Short-Chain Fatty Acids: Key Factors in Pediatric Obesity and Therapeutic Targets
Pînzariu, A. C., Leonte, S. M., Trofin, A. G., Trandafir, L. M., Moscalu, M., Manole, L. M., Moscalu, R., Lazăr, C. I., Confederat, L. G., Vlăsceanu, V. I., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311503 · Cited by 9
“It should also be noted that SCFAs can regulate the production of neurotransmitters, contributing to the improvement of symptoms related to ASD, because of the extensive interaction within the gut–brain axis in which microbiota metabolites actively participate [215–217].”
The Long and Winding Road to Understanding Autism
Manzo, J., Hernández‐Aguilar, M. E., Toledo‐Cárdenas, M. R., Herrera‐Covarrubias, D., Coria‐Ávila, G. A., Libreros-Jiménez, H. M., Cañedo, L. F., & Pineda, L. A. O. (2025) · NeuroSci · doi:10.3390/neurosci6030084 · Cited by 7
“Such alterations may be compounded by the highly selective and restricted diets common in ASD, which are often low in fiber and high in processed foods, reducing beneficial SCFA-producing bacteria [192,193].”
Mavridou, M., Kyriazidi, M. A., Varlamis, S., Skepastianos, P., Mitka, S., Papaliagkas, V. T., & Chatzidimitriou, M. (2025) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2025.02663 · Cited by 6
Liao, X., Li, H., Han, K., Long, J., Liu, Y., Tang, Z., Chen, J., Liu, H., & Zhang, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07754-6 · Cited by 4
“This activates the peripheral immune system and releases inflammatory mediators such as IL-6, TNF-α, and IL-17a [302].”
Xu, T., Roy, S. P., Hadia, R., Annu, Bhowmik, S., & Panchal, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1826681 · Cited by 4
Malode, T. D., Chandurkar, P. A., Taksande, B. G., Tatode, A., Qutub, M., Premchandani, T., Umekar, M. J., & Taksande, J. (2025) · Medicine in Microecology · doi:10.1016/j.medmic.2025.100138 · Cited by 3
Role of Gut Microbiota in Psychiatric Disorders: From Mechanistic Insights to Therapeutic Strategies
Kim, Y. S., Woo, S., Ha, E., Ahn, S., Kim, E., Kim, S. I., Lim, W., & Kim, S. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e78 · Cited by 3
“104 Faecalibacterium prausnitzii , a key bacterium that produces butyrate and exhibits anti-inflammatory properties, tends to be consistently reduced in patients with depression, a pattern observed across nearly all studies investigating the link between gut microbiota and depression.”
Sivamaruthi, B. S., Kesika, P., Chaiyasut, C., & Varman, D. R. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1750377 · Cited by 4
“…targeted interventions, such as probiotics, prebiotics, dietary modulation, or inhibition of microbial decarboxylase activity, may provide novel strategies to restore dopaminergic balance in disorders ranging from depression to PD (Ahmed et al., 2024; Młynarska et al., 2025; Miyaue et al., 2025).”
Azimzadeh, M., & Azimzadeh, M. (2026) · Behavioural Brain Research · doi:10.1016/j.bbr.2026.116404 · Cited by 2
Feng, P., Han, Y., Xue, X., Li, H., Zhao, Y., Zhao, P., Zhao, S., & Li, E. (2026) · Food & Function · doi:10.1039/d5fo05023e · Cited by 1
Devi, S., Debnath, N., Yadav, P., Satyavolu, S., Yadav, A. K., & Tyagi, N. (2026) · Comprehensive physiology · doi:10.1002/cph4.70165 · Cited by 1
Stanković, V. V., Jovic, D. P., & Rancic, N. K. (2026) · Microbiology Research · doi:10.3390/microbiolres17070124 · Cited by 1
“These include maternal stress, substance use, toxin exposure, preterm birth, low birth weight, cesarean delivery, environmental pollutants, allergies, gut microbiota disturbances, and limited breastfeeding [40].”
Zhao, S., Sun, M., Li, H., Wang, Z., Meng, Z., Xu, Y., Mao, S., Wang, W. J., & Sun, H. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1806688 · Cited by 1
Torales, J. C., Torres-Romero, A. D., Vera-Villanueva, G., Villalba-Ávalos, M., Roa-Peña, A., Ayala-Páez, E., Giménez-Correa, L., O’Higgins, M. G., Caycho‐Rodríguez, T., Castaldelli-Maia, J. M., et al. (2025) · Psychology Health & Medicine · doi:10.1080/13548506.2025.2565519
Lifestyle, Diet, and the Gut–Brain Axis in Neuroprotection
Sharma, P., Verma, N., Verma, A., Wal, A., Kumar, S., & Upadhyay, P. (2025) · Springer eBooks · doi:10.1007/978-981-95-3945-1_16
Relationship Between Microbiota and Mental Health: A Holistic View
Kaplan, V., Bilden, A., & Kaplan, Ö. (2026) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1733271 · Cited by 1
Şahin, B., & Osmanlı, C. Ç. (2025) · European Journal of Therapeutics · doi:10.58600/eurjther2832 · Cited by 2
“Importantly, the gut microbiome is thought to influence brain function through the production of short-chain fatty acids, modulation of neurotransmitter pathways, and regulation of immune responses, thereby contributing to neuroinflammation and ASD pathophysiology [39-40].”
İnsan Mikrobiyomu: Sağlık ve Hastalık Üzerindeki Etkileri
Öztürk, A. (2025) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.3834.c1059
Protic, D. D., Nikolić, V., & Stojković, M. (2025) · Medicinski podmladak · doi:10.5937/mp76-60614
雪, 欣. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161043
Shi, H., Zhang, L., Fang, F., Zhang, Y., Xu, X., Gou, L., Tang, X. C., Wang, H., Cui, L., Song, H., et al. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1759221
Serpa, J. J. V., & Cano, S. S. (2026) · Nutrición Hospitalaria · doi:10.20960/nh.06516 · Cited by 1
Smolko, N. A., Fayzullina, R. A., Mukhamedshina, Y. O., Synbulatova, G. E., & Markelova, M. (2026) · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · doi:10.21508/1027-4065-2026-71-2-57-65
The Microbiome-Body Connection: Unraveling the Gut-Brain Axis
Islam, M. M., Mahbub, N. U., & Islam, M. A. (2026) · Springer eBooks · doi:10.1007/978-981-95-7494-0_1 · Cited by 1
Microbial dial: How the gut microbiome tunes the severity of autism spectrum disorder
Nagamine, T. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.116755
Al‐Beltagi, M., Saeed, N. K., & Elbeltagi, Y. M. (2026) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.121115
Dolidze, K., & Tchedia, R. (2026) · World Journal of Biology Pharmacy and Health Sciences · doi:10.30574/wjbphs.2026.26.2.0309
Roles of histone lysine methylation in neurodevelopment and related disorders
Chen, Y., Zhang, Y., Zhang, H., & Liang, X. (2026) · Ibrain · doi:10.1002/ibra.70022
“156 Additional dietary approaches — such as plant ‐ based diets, 157 the Mediterranean diet, 158 dietary antioxidants, 159 and neuroprotective nootropic foods 160 — offer non ‐ pharmacologic avenues to ameliorate NDDs symptoms.”
Wang, Q., Zheng, W., Zhang, C., Lv, S., Peng, L., Chen, J., & Lu, A. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102315
The gut microbiota, neurodevelopment and autism spectrum disorder: A close connection
Guo, Y., Liu, A., Hao, X., Cao, X., Li, Y., & Liu, X. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111811
Gut microbiota from health to disease: A role for biofilms?
Buret, A. G., & Allain, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00011-9 · Cited by 1
Short‐Chain Fatty Acid–Dependent Neuroimmune Regulation in Autism Spectrum Disorder Pathogenesis
Dhungel, A., & Bora, R. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70637 · Cited by 3
“Further, anti-inflammatory cytokines like IL-4 and IL-10 are also known to be increased in ASD children (Młynarska et al. 2025).”
Safety of Fecal Microbiota Transplantation in Children: A Single-Center Experience
Varnas, D., & Urbonas, V. (2026) · Children · doi:10.3390/children13081005
“…across a range of other conditions: gastrointestinal ones including inflammatory bowel disease (IBD) [9], irritable bowel syndrome (IBS) [10], and constipation [11], and neuropsychiatric ones such as autism spectrum disorder (ASD) [12], Parkinson’s disease [13], and anorexia nervosa [14,15].”
Santos, E. B., Cunha, C. F. D. S. B., Maslinkiewicz, A., de Lima, A. J. A., LOPES, M. E. A., Estrada, L. J. G., Moreira, K. N., FERREIRA, G. T. M., Oliveira, L. R., & Fazan, V. P. S. (2026) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v7i8.8758 · Cited by 1
Japaridze, N. J., Khomasuridze, P., Zhvania, M. G., Lobzhanidze, G., Tizabi, Y., Rzayev, F., Gasimov, E. K., & Pochkhidze, N. (2026) · Brain Research · doi:10.1016/j.brainres.2026.150529
Novel microbiota and the gut-brain axis in individuals with autism spectrum disorder
Kirdar, Z. M., Hamad, H. Y., & Auda, I. G. (2026) · Scientific Reports · doi:10.1038/s41598-026-71422-4
“This inflammatory cascade has been shown to disrupt neural connectivity and manifest as behavioural impairments associated with ASD 9,103,104 .”
He, Y., Lin, F., Huang, H., & Chen, Q. (2026) · Medicine · doi:10.1097/md.0000000000051247
“[6,7] Increasing evidence from animal models, clinical studies, and multi-omics approaches shows that individuals with ASD often experience significant imbalances in their gut microbial communities, accompanied by altered metabolic profiles.”
Mashayekhpour, M. A., Amani, H., Moghaddam, A. H., Moradi, A., Nohesara, S., & Abdolmaleky, H. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27219502
The Microbiota-Gut-Brain Axis in Neurological and Neuropsychiatric Disorders: A Literature Review
Brar, H., Do, N., Kelser, C., Pattipati, S. N., & Nalamolu, K. R. (2026) · Cureus · doi:10.7759/cureus.118684
Ye, Z. (2026) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps/2026.40.17027.1
Zheng, Y., & Zhao, M. (2026) · Molecules · doi:10.3390/molecules31213952
Yu, X., He, J., & Liu, M. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579117
Metadata
- Authors
- Młynarska, E., Barszcz, E., Budny, E., Gajewska, A., Kopeć, K., Wasiak, J., Rysz, J., & Franczyk, B.
- Affiliations
- Medical University of Lodz (PL)
- Corresponding author
- Młynarska, Ewelina
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-03-25
- Volume
- 17
- Issue
- 7
- Pages
- 1135
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC11990867
- OpenAlex
- W4408830734
- Cited by
- 44
- References
- 144
- Citations by year
- 2026: 29 · 2025: 15
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- autism spectrum disorder, gut-brain axis, gut microbiota, dysbiosis, short-chain fatty acids, neurotransmitter modulation, neuroinflammation, gastrointestinal symptoms, behavioral symptoms, gluten-free diet, antioxidant diet, probiotics, fecal microbiota transplantation, personalized treatment, microbiome diversity
- MeSH terms
- Autism Spectrum Disorder, Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Brain-Gut Axis, Brain, Humans, Probiotics, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
